About IO Biotech
We are a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on our T-win technology platform.
Our product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
We aim to disrupt the way cancer is treated with our approach, solidifying our product candidates as the cornerstones for multiple solid tumors.
Leadership
We have assembled a seasoned management team with extensive experience in developing novel oncology therapies, including advancing product candidates from preclinical research through to clinical development, and ultimately to regulatory approval.
Mai-Britt Zocca, Ph.D.
Member - President and Chief Executive Officer
Amy Sullivan
Chief Financial Officer
Eva Ehrnrooth, M.D., Ph.D.
Chief Medical Officer
Muhammad Al-Hajj, Ph.D.
Chief Scientific Officer
Diane McDowell
SVP, Clinical Development and Medical Affairs
Dan Mannix
SVP, Regulatory Affairs
Eric Faulkner
Senior Vice President, CMC
Brian Burkavage
Chief Accounting Officer
Board of Directors
Our board of directors has deep expertise in the fields of immuno-oncology, business and finance.
Peter Hirth, Ph.D.
Chairman
Kathleen Sereda Glaub, M.B.A.
Member
Christian Elling, Ph.D.
Member – Lundbeckfonden
Priyanka Belawat, Ph.D.
Member – HBM Healthcare Investments
Jack B. Nielsen, M. Sc.
Member - Vivo Capital
Vanessa Malier
Member – Kurma Partners
David V. Smith
Member
Mai-Britt Zocca, Ph.D.
Member - President and Chief Executive Officer
Scientific Advisory Board
Kapil Dhingra, MD, Ph.D.
Strategic R&D Advisor
Professor Mads Hald Andersen, MD, Ph.D.
Founder, Scientific Advisor
Professor, MD, Ph.D. Inge Marie Svane
Founder, Clinical Advisor
Alexander Eggermont, MD, PhD, Professor
Clinical advisor